Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.75 |
| ▸ | MRE11 | P49959 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darbufelone SCHEMBL452950 | 1.00 | PTGS2 (0.75) | PTGS2PTGS1MRE11CYP1A2CYP2C9 | |
| Darbufelone SCHEMBL8526046 | 1.00 | PTGS2 (0.75) | PTGS2PTGS1MRE11CYP1A2CYP2C9 | |
| Darbufelone SCHEMBL2683037 | 0.94 | PTGS2 (0.67) | PTGS2PTGS1MRE11CYP1A2CYP2C9 | |
| SCHEMBL3667218 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1GAAALOX5 | |
| SCHEMBL3667216 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1GAAALOX5 | |
| SCHEMBL8962138 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1GAAALOX5 | |
| SCHEMBL8618544 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1GAAMEN1KMT2A | |
| SCHEMBL8309757 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1GAAMEN1KMT2A | |
| SCHEMBL7768284 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1GAAMEN1KMT2A | |
| SCHEMBL8492533 | 0.82 | PTGS2 (0.51) | PTGS2PTGS1MRE11CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0914122-B1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER LAMBERT CO (US) | 2003-09-24 | — | — | EP | claimed |
| EP-0914122-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1999-05-12 | — | — | EP | claimed |
| WO-1998002160-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1998-01-22 | — | — | WO | claimed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | BROUGH STEPHEN (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-8299246-B2 | N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses | ASTRAZENECA AB (SE) | 2012-10-30 | — | — | US | disclosed |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | ASTRAZENECA AB (SE) | 2012-08-23 | — | — | US | disclosed |
| EP-0914122-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| EP-0914122-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998002160-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002160-A1 | METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS BY ADMINISTERING A THIAZOLIDINONE | WARNER-LAMBERT COMPANY (US) | 1998-01-22 | — | — | WO | disclosed |
| US-5494927-A | INHIBITS ACTIVITY OF 5-LIPOXYGENASE AND-OR CYCLOOXYGENASE | WARNER-LAMBERT COMPANY (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0449216-B1 | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents | WARNER LAMBERT CO (US) | 1996-02-07 | — | — | EP | disclosed |
| US-5290800-A | Enzyme inhibitors | WARNER-LAMBERT COMPANY (US) | 1994-03-01 | — | — | US | disclosed |
| US-5143928-A | Inhibitors of cyclooxygenase and lipoxygenase | WARNER-LAMBERT COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0449216-A1 | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, CYP3A5 | PTGS2 1752/4885PTGS1 1976/4885MRE11 4885/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | PTGS2 2891/4885PTGS1 2476/4885MRE11 4669/4885 |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | PTGS2 2393/4885PTGS1 2409/4885MRE11 4333/4885 |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | CYP3A7, CYP3A5, CYP2C19 | PTGS2 3832/4885PTGS1 3607/4885MRE11 4863/4885 |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | PTGS2 2978/4885PTGS1 3031/4885MRE11 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.